(Reuters) – Biogen Inc said on Wednesday it would terminate a post-approval study of its first Alzheimer’s drug, Aduhelm, and discontinue all commercialization for the controversial treatment. The strategic shift …
Tag:
aduhelm
-
-
– U.S. Secretary of Health and Human Services Xavier Becerra on Monday asked the country’s Medicare program to reassess its 2022 premium hikes, weeks after Biogen Inc cut the price …